
Chinese General Practice ›› 2026, Vol. 29 ›› Issue (21): 3040-3045.DOI: 10.12114/j.issn.1007-9572.2024.0602
• Article·Research Trends of Traditional Chinese Medicine • Previous Articles
Received:2025-03-10
Revised:2025-12-15
Published:2026-07-20
Online:2026-06-03
Contact:
HUANG Hongxing
通讯作者:
黄宏兴
作者简介:作者贡献:
林燕平进行文章的构思与设计,负责撰写论文;黄佳纯负责研究的实施;郭海威、赵瑞、杨昊霖进行数据收集、整理;万雷、朱根福负责研究的可行性分析;黄宏兴负责文章的质量控制及审校,对文章整体负责,监督管理。
基金资助:CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2024.0602
| 组别 | 例数 | 年龄(岁) | BMI(kg/m2) | 骨矿含量(g) | 脂肪质量(g) | 肌肉质量(g) |
|---|---|---|---|---|---|---|
| 肝肾阴虚组 | 39 | 61.6±6.4 | 22.4±2.0 | 1 532.8±230.5 | 19 169.1±3 095.0 | 33 511.4±3 499.5 |
| 脾肾阳虚组 | 53 | 63.5±7.9 | 21.9±3.2 | 1 667.2±313.7a | 17 439.6±4 236.3a | 35 162.4±5 989.6 |
| 气滞血瘀组 | 16 | 64.8±6.2 | 23.7±3.5 | 1 701.3±257.6a | 20 540.9±4 236.3b | 36 055.1±3 178.9 |
| F值 | 1.26 | 2.21 | 3.35 | 3.82 | 1.71 | |
| P值 | 0.29 | 0.11 | 0.04 | 0.01 | 0.14 |
Table 1 Comparison of general conditions of patients with different syndrome types
| 组别 | 例数 | 年龄(岁) | BMI(kg/m2) | 骨矿含量(g) | 脂肪质量(g) | 肌肉质量(g) |
|---|---|---|---|---|---|---|
| 肝肾阴虚组 | 39 | 61.6±6.4 | 22.4±2.0 | 1 532.8±230.5 | 19 169.1±3 095.0 | 33 511.4±3 499.5 |
| 脾肾阳虚组 | 53 | 63.5±7.9 | 21.9±3.2 | 1 667.2±313.7a | 17 439.6±4 236.3a | 35 162.4±5 989.6 |
| 气滞血瘀组 | 16 | 64.8±6.2 | 23.7±3.5 | 1 701.3±257.6a | 20 540.9±4 236.3b | 36 055.1±3 178.9 |
| F值 | 1.26 | 2.21 | 3.35 | 3.82 | 1.71 | |
| P值 | 0.29 | 0.11 | 0.04 | 0.01 | 0.14 |
| 组别 | 例数 | 25(OH)D(nmol/L) | 1,25-(OH)2D(ng/L) | FGF-23(pg/mL) | SEMA4D(pg/mL) | sRANKL(ng/L) |
|---|---|---|---|---|---|---|
| 肝肾阴虚组 | 39 | 62.0±12.8 | 1 269.8±760.0 | 845.8±449.2 | 1 121.9±520.1 | 755.0±487.4 |
| 脾肾阳虚组 | 53 | 56.6±13.3 | 1 265.2±958.2 | 782.0±444.8 | 1 103.9±634.0 | 712.3±580.4a |
| 气滞血瘀组 | 16 | 58.0±10.3 | 1 954.5±1 751.2 | 1 047.8±558.3 | 1 373.1±906.7 | 739.2±431.2 |
| F值 | 2.07 | 2.92 | 2.01 | 1.13 | 0.08 | |
| P值 | 0.13 | 0.06 | 0.14 | 0.33 | 0.93 |
Table 3 Comparison of bone fat metabolism level among different TCM syndrome types
| 组别 | 例数 | 25(OH)D(nmol/L) | 1,25-(OH)2D(ng/L) | FGF-23(pg/mL) | SEMA4D(pg/mL) | sRANKL(ng/L) |
|---|---|---|---|---|---|---|
| 肝肾阴虚组 | 39 | 62.0±12.8 | 1 269.8±760.0 | 845.8±449.2 | 1 121.9±520.1 | 755.0±487.4 |
| 脾肾阳虚组 | 53 | 56.6±13.3 | 1 265.2±958.2 | 782.0±444.8 | 1 103.9±634.0 | 712.3±580.4a |
| 气滞血瘀组 | 16 | 58.0±10.3 | 1 954.5±1 751.2 | 1 047.8±558.3 | 1 373.1±906.7 | 739.2±431.2 |
| F值 | 2.07 | 2.92 | 2.01 | 1.13 | 0.08 | |
| P值 | 0.13 | 0.06 | 0.14 | 0.33 | 0.93 |
| 组别 | 例数 | 25(OH)D(nmol/L) | 1,25-(OH)2D(ng/L) | FGF-23(pg/mL) | SEMA4D(pg/mL) | sRANKL(ng/L) |
|---|---|---|---|---|---|---|
| 肝肾阴虚组 | 19 | 61.2±12.5 | 1 181.3±508.4 | 826.4±406.8 | 1 020.3±400.6 | 702.0±286.4 |
| 脾肾阳虚组 | 20 | 54.0±9.3 | 979.5±334.7 | 684.5±325.9 | 918.9±827.2 | 514.9±142.3a |
| 气滞血瘀组 | 2 | 67.7±19.1 | 1 520.7±681.1 | 1347.8±100.8 | 1 541.5±149.4 | 617.5±41.1 |
| F值 | 2.77 | 2.02 | 2.74 | 2.60 | 3.48 | |
| P值 | 0.08 | 0.15 | 0.08 | 0.09 | 0.04 |
Table 3 Levels of bone fat metabolism in different syndrome groups of patients with severe osteoporosis
| 组别 | 例数 | 25(OH)D(nmol/L) | 1,25-(OH)2D(ng/L) | FGF-23(pg/mL) | SEMA4D(pg/mL) | sRANKL(ng/L) |
|---|---|---|---|---|---|---|
| 肝肾阴虚组 | 19 | 61.2±12.5 | 1 181.3±508.4 | 826.4±406.8 | 1 020.3±400.6 | 702.0±286.4 |
| 脾肾阳虚组 | 20 | 54.0±9.3 | 979.5±334.7 | 684.5±325.9 | 918.9±827.2 | 514.9±142.3a |
| 气滞血瘀组 | 2 | 67.7±19.1 | 1 520.7±681.1 | 1347.8±100.8 | 1 541.5±149.4 | 617.5±41.1 |
| F值 | 2.77 | 2.02 | 2.74 | 2.60 | 3.48 | |
| P值 | 0.08 | 0.15 | 0.08 | 0.09 | 0.04 |
| 骨矿含量 | 脂肪质量 | 肌肉质量 | 25(OH)D | 1,25-(OH)2D | FGF-23 | SEMA4D | sRANKL | |
|---|---|---|---|---|---|---|---|---|
| 骨矿含量 | 1 | |||||||
| 脂肪质量 | 0.223a | 1 | ||||||
| 肌肉质量 | 0.572a | 0.349a | 1 | |||||
| 25(OH)D | -0.099 | 0.173 | 0.006 | 1 | ||||
| 1,25-(OH)2D | 0.091 | 0.300a | 0.099 | 0.244a | 1 | |||
| FGF-23 | -0.057 | 0.219a | 0.016 | 0.410a | 0.669a | 1 | ||
| SEMA4D | 0.123 | 0.272a | 0.021 | 0.357a | 0.747a | 0.793a | 1 | |
| sRANKL | 0.036 | 0.267a | 0.007 | 0.287a | 0.696a | 0.433a | 0.639a | 1 |
Table 5 Correlation between bone mineral content, fat mass, muscle mass and biochemical indexes of bone metabolism
| 骨矿含量 | 脂肪质量 | 肌肉质量 | 25(OH)D | 1,25-(OH)2D | FGF-23 | SEMA4D | sRANKL | |
|---|---|---|---|---|---|---|---|---|
| 骨矿含量 | 1 | |||||||
| 脂肪质量 | 0.223a | 1 | ||||||
| 肌肉质量 | 0.572a | 0.349a | 1 | |||||
| 25(OH)D | -0.099 | 0.173 | 0.006 | 1 | ||||
| 1,25-(OH)2D | 0.091 | 0.300a | 0.099 | 0.244a | 1 | |||
| FGF-23 | -0.057 | 0.219a | 0.016 | 0.410a | 0.669a | 1 | ||
| SEMA4D | 0.123 | 0.272a | 0.021 | 0.357a | 0.747a | 0.793a | 1 | |
| sRANKL | 0.036 | 0.267a | 0.007 | 0.287a | 0.696a | 0.433a | 0.639a | 1 |
| [1] |
|
| [2] |
中国疾病预防控制中心慢性非传染性疾病预防控制中心, 中华医学会骨质疏松和骨矿盐疾病分会. 中国骨质疏松症流行病学调查报告-2018[M]. 北京: 人民卫生出版社, 2021.
|
| [3] |
中华医学会骨质疏松和骨矿盐疾病分会, 章振林, 夏维波, 等. 原发性骨质疏松症诊疗指南(2022)[J]. 中国全科医学, 2023, 26(14): 1671-1691. DOI: 10.12114/j.issn.1007-9572.2023.0121.
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
广东省中医药学会. 《原发性骨质疏松症(骨痿)中医临床诊疗指南》[Z]. 2021.
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
王庆谚, 李佳, 郑洪新. 从"肾虚络病,瘀阻骨络"探讨原发性骨质疏松症中医病机[J]. 中华中医药杂志, 2022, 37(2): 756-759.
|
| [13] |
张萌萌, 张岩, 吴涤, 等. 骨代谢生化指标实验推荐方案[J]. 中国骨质疏松杂志, 2021, 27(10): 1405-1412, 1549. DOI: 10.3969/j.issn.1006-7108.2021.10.001.
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
钱朝良, 邢涛, 李向洲, 等. FGF23对慢性肾脏病的矿物质和骨代谢异常的作用及中药干预的研究[J]. 中国骨质疏松杂志, 2024, 30(2): 263-269, 289.
|
| [21] |
|
| [22] |
龚华乾, 田兴中, 陈雨佳, 等. 黄芪多糖对地塞米松诱导的MC-3T3-E1成骨细胞FGF23、Klotho mRNA及蛋白表达的影响[J]. 时珍国医国药, 2023, 34(6): 1349-1353.
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
梁影影, 王国玉, 康大伟, 等. 慢性心力衰竭患者血清OPG、sRANKL与骨质疏松相关分析[J]. 中国骨质疏松杂志, 2022, 28(12): 1796-1799, 1807. DOI: 10.3969/j.issn.1006-7108.2022.12.017.
|
| [1] | LI Shilong, WANG He, ZHOU Xiaoyu, FU Lei, ZHAO Zhuo, HUA Chengjun, SI Chunying. Advances in the Study of Cardiac Macrophages in Heart Failure with Preserved Ejection Fraction [J]. Chinese General Practice, 2026, 29(15): 2084-2091. |
| [2] | HE Xiaoming, HE Mincong, WEI Tengfei, LIN Tianye, LIU Wengang, ZHANG Qingwen, HE Wei, WEI Qiushi. Multidimensional Relationship of "TCM Syndrome Type, Clinical Feature and Molecular Typing" in Postmenopausal Patients with Knee Osteoarthritis [J]. Chinese General Practice, 2026, 29(12): 1588-1598. |
| [3] | ZHANG Hanzhi, JIN Hua, MA Le, SHI Ling, CHEN Chen, HUAN Hongmei, YU Dehua. Analysis of the Quality of Diagnosis and Treatment of Osteoporosis in Shanghai Community Health Service Institutions [J]. Chinese General Practice, 2026, 29(12): 1548-1557. |
| [4] | YANG Yang, GAO Xi. Research Progress of Paradoxical Bone Formation in Osteoporosis [J]. Chinese General Practice, 2026, 29(09): 1217-1224. |
| [5] | ZHANG Yuan, CHEN Guanhua, LYU Shanshan, JING Yali. Relationship between Thyroid Hormone Sensitivity Indices and Osteoporosis in Patients with Normal Thyroid Function Type 2 Diabetes Mellitus [J]. Chinese General Practice, 2025, 28(29): 3653-3659. |
| [6] | GAO Guiying, HU Yang, ZHANG Shiyi, MENG Yi, DENG Jie. Research Progress on the Mechanism of Exercise Rehabilitation in Improving Coronary Microcirculation Disorder [J]. Chinese General Practice, 2025, 28(20): 2570-2576. |
| [7] | XIONG Xin, LI Yang, SHI Feng, YANG Lian, DUAN Wei, CHEN Bei, LI Yong, ZHAO Linwei, FU Quanshui, FAN Xiaoping, YANG Guoqing. Research on the Measurement System and Calibration of Thoracolumbar Vertebral Density Based on Artificial Intelligence [J]. Chinese General Practice, 2025, 28(19): 2398-2406. |
| [8] | TAN Wenbin, LI Jia, LIU Mingyu, LU Yongxin, CHENG Yaxin. Research Progress on the Influence of Nervous System Diseases and Related Therapeutic Drugs on Osteoporosis [J]. Chinese General Practice, 2025, 28(17): 2092-2100. |
| [9] | HE Ting, LI Jia, TAN Wenbin. Research Progress of Circulatory System Diseases and Secondary Osteoporosis [J]. Chinese General Practice, 2025, 28(17): 2101-2112. |
| [10] | CHEN Beibei, LI Jia, TAN Wenbin. Progress in the Research of Endocrine and Metabolic System Diseases and Secondary Osteoporosis [J]. Chinese General Practice, 2025, 28(17): 2082-2091. |
| [11] | LI Jia, TAN Wenbin. The Dilemma of Prevention and Treatment of Secondary Osteoporosis and Its Countermeasures [J]. Chinese General Practice, 2025, 28(17): 2075-2081. |
| [12] | SUN Qing, WU Yuxiao, CUI Limin. The Prevalence of Osteosarcopenia in Chinese Patients with Type 2 Diabetes Mellitus: a Meta-analysis [J]. Chinese General Practice, 2025, 28(12): 1520-1526. |
| [13] | YANG Chaofu, TAN Guoqing, XU Zhanwang. Research Progress on the Regulation Mechanism of Senescence-associated Secretory Phenotype in Osteoporosis [J]. Chinese General Practice, 2024, 27(29): 3685-3695. |
| [14] | SU Jin, SHOU Juan, GU Wenqin, YI Chuntao, XU Liping, CHENG Lili, DING Hongjuan, ZHOU Peng, WU Yinghua, QIN Jie, XUE Bin, WEI Baichuan, WANG Qian, PENG Yan, CHENG Yimin, YANG Lan, WEI Yangyang, WANG Lei, QI Jinlin, SHAO Ying, CAI Liming. Cost Effectiveness Analysis of the Prevention and Treatment of Osteoporosis among the Entire Population in Fenglin Community, Shanghai Based on Markov Chain [J]. Chinese General Practice, 2024, 27(22): 2789-2796. |
| [15] | LIAO Yanping, LI Yunyi, ZHOU Zhiheng, WANG Haoxiang. Prevalence and Root Cause Analysis of Adiposity-based Chronic Disease in Older Adults Aged 65 Years and Older [J]. Chinese General Practice, 2024, 27(19): 2357-2363. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||